Kioxia’s AI Project Wins 2020 Field Innovation Award Silver Prize From Japanese Society for Artificial Intelligence
22.6.2021 11:57:00 EEST | Business Wire | Press release
Kioxia Corporation, a world leader in memory solutions, announced today that it was awarded the 2020 Field Innovation Award Silver Prize by the Japanese Society for Artificial Intelligence (JSAI) for its TEZUKA 2020 project. TEZUKA 2020 brought AI and humans together in collaboration to create a new manga, or comic book, in the nearly identical artistic style of manga legend Osamu Tezuka.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005554/en/
Plot development (Graphic: Business Wire)
The Field Innovation Award recognizes individuals and organizations that leverage AI technology to solve real-life issues and advance the state of business and society.
The TEZUKA 2020 project was acclaimed as an innovative use of AI technology to develop a new manga, which involves combining numerous elements of storytelling, including location settings, characters, plot development, dialogues, panel layouts and speech bubbles. Through the AI technology, the project team created prototypes for new plots and characters, all while honoring the unique and highly recognizable Tezuka style. Human artists then used these AI-created prototypes to develop a complete, full-length manga entitled “PHAEDO.”
Kioxia, guided by its mission of uplifting the world with memory, uses AI technology to support creativity as well as to improve production efficiency and quality through memory solutions.
The members of the TEZUKA 2020 project are as follow:
- Hitoshi Matsubara, Professor at the University of Tokyo
- Satoshi Kurihara, Professor at Keio University
- Kazushi Mukaiyama, Professor at Future University Hakodate
- Yoji Kawano, Assistant Professor at Keio University
- Atsushi Nakajima, Digital Transformation Technology R&D Center, Kioxia Corporation
- Atsushi Kunimatsu, SSD Division, Kioxia Corporation
- Masato Ishiwata, Director of Creative Division, Tezuka Productions
- Makoto Tezuka, Director at Tezuka Productions
- Daisuke Tsutsui, Director of Brand & Innovation Division, Wunderman Thompson Tokyo
- Ryohei Orihara, Digital Transformation Technology R&D Center, Kioxia Corporation
Creating plots with AI
To enable AI to learn the essence of Tezuka’s works and artistry, 130 of his creations were deconstructed and split into 13 common plot development phases to be used as data. The AI technology used that data to generate story outlines (Figure 1), generating over 100 plots in total. Thereafter, the project members discussed the storyline options, some of which had highly unexpected twists that people would not likely have imagined, and ultimately selected the plot that became the basis of “PHAEDO.”
Creating characters with AI
This project used an AI technology called Generative Adversarial Networks (GAN), which learned Tezuka’s authentic artistry to generate characters that were extremely close to his style. Some 4,500 facial images were gathered, but only a small number of the images were ideally suited to machine learning due to their orientation and proportions (Figure 2). To enable the AI to learn the characteristics of Tezuka’s illustrated human faces, the project team introduced a process called “transfer learning” to the AI technology, allowing it to accurately learn Tezuka’s manga characters and generate its own characters in his unique style (Figure 3).
About Kioxia
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with memory by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005554/en/
Contact information
Kota Yamaji
Public Relations
Kioxia Holdings Corporation
81-3-6478-2319
kioxia-hd-pr@kioxia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
